Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Study Demonstrates Rotigotine Improves Symptoms of Early-Stage Parkinson's Disease CHICAGO, IL -- September 21, 2005 -- Rotigotine, which is currently under investigation for Parkinson's disease (PD), improved symptoms associated with early-stage PD, according to data presented here on September 19th at the 9th European Federation of Neurological Societies (EFNS). In addition, data from a second phase 3 trial showed rotigotine also reduced "off" time and increased "on" time without troublesome dyskinesias in patients with advanced-stage PD already taking levodopa. Rotigotine, a non-ergolinic dopamine agonist formulated as a patch, is under investigation for the treatment of Parkinson's disease. The patch, applied once-daily in clinical trials, is designed to continuously deliver rotigotine to the bloodstream through the skin (transdermally). Data presented at EFNS indicated that in a clinical trial, rotigotine patch provides stable blood plasma levels of the medication over a 24-hour period. Schwarz Pharma filed a New Drug Application (NDA) for rotigotine in the treatment of PD with the U.S. Food and Drug Administration (FDA) in January 2005 and with the European Agency for the Evaluation of Medicinal Products (EMEA) in September 2004 for the treatment of early-stage Parkinson's disease. These applications are still under review. Rotigotine in the treatment of early-stage PD Werner Poewe, MD, of Innsbruck Medical University, Innsbruck, Austria, presented data on the effect of rotigotine on patients with early-stage PD. In this double-blind, placebo-controlled, two-part study, 273 patients with early-stage PD were assigned to receive either rotigotine (n=177) or placebo (n=96) for 6 months. For the rotigotine treatment, patients were started on a 10 cm2 (delivering 2 mg/day) patch, increasing the patch size by 10 cm2 each week over 3 weeks to a maximum patch size of 30 cm2 (delivering 6 mg/day). The researchers measured changes in scores on parts II and III of the Unified Parkinson Disease Rating Scale (UPDRS). These two parts of the UPDRS assess a patient's ability to perform activities of daily living such as feeding and dressing oneself and evaluate motor symptoms of PD including tremor and rigidity. During the study, patients in the rotigotine group showed an average improvement of 3.8 points in their UPDRS scores from baseline (their scores measured at the beginning of the study) compared to the placebo group, whose scores worsened by an average of 1.5 points from baseline. Ninety-seven percent of patients who completed the study continued on rotigotine in an open-label extension of the trial. The most common adverse events (AEs) observed in study participants were application site reactions, nausea, somnolence (sleepiness) and dizziness. Rotigotine as an adjunctive therapy in patients with advanced-stage PD Peter LeWitt, MD, professor of neurology and psychiatry at Wayne State University School of Medicine in Detroit, Michigan, and a clinical professor in the department of neuroscience at William Beaumont Hospital Research Institute in Royal Oak, Michigan, presented findings on rotigotine as an adjunctive treatment for advanced-stage PD. In a phase 3, double-blind, multicenter trial, 341 patients with advanced-stage PD being treated with levodopa were randomly assigned to additional therapy with two different strengths of rotigotine or placebo. Treatment groups included a rotigotine patch size of 40 cm2 (delivering 8 mg/day; n=113), a rotigotine patch size equivalent of 60 cm2 (delivering 12 mg/day; n=109) or placebo (n=119). Patients assigned to the 40 cm2 rotigotine group experienced an average reduction in "off" time of 2.7 hours over a 24-hour period compared to baseline. Patients assigned to the 60 cm2 rotigotine group experienced an average reduction of 2.1 hours in "off" time over a 24-hour period compared to baseline and patients assigned to the placebo group experienced an average reduction of 0.9 hours in "off" time compared to baseline. Ninety-nine% of patients who completed the study continued on rotigotine in an open-label extension of the trial. The most common AEs observed in study participants were application site reactions, somnolence (sleepiness), nausea and dizziness. An estimated 4 million people suffer from PD worldwide, including about 1.5 million Americans. Patients with PD often experience trouble walking, tremors, dyskinesia, rigidity, slowness of movement (bradykinesia) and impaired balance. Symptoms of PD may appear at any age, but the average age of onset is 60 years. Young-onset PD (age 40 or younger) is estimated to occur in five to ten% of patients. Roughly five to ten% of PD patients have a family history of PD, suggesting that a genetic factor may be involved. Dopamine agonists are an important pharmacologic component in the treatment of PD and mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. Dopamine-producing cells in the brain become damaged and die in patients with PD, resulting in a variety of motor coordination disorders. SOURCE: Schwarz Pharma, Inc. E-mail this page to a friend or colleague! To print, use this version